Haemonetics (HAE) Aktie Kurs
Haemonetics Kurs
Under de senaste 19 åren växte Haemonetics intäkterna med 5,9 % årligen och nådde 1,33 Mrd USD. Vinst per aktie har vuxit med 4,5 % per år under de senaste 19 åren. För Haemonetics är nettovinstmarginal på 7,3 % upp jämfört med 4,4 % för några år sedan. Det konsensusbaserade 12-månaderskursmålet för Haemonetics är 96,00 USD, cirka under kursen med 20,0 %. Av 15 analytiker ger 12 köpråd — den samlade bedömningen är Köp.
Haemonetics aktiekurs
Hämta dessa data via Eulerpool API
100 000 anrop/mån gratis · inget kreditkort
Haemonetics affärsmodell och aktieanalys
Vanliga frågor om Haemonetics-aktien
The business model of Haemonetics Corp focuses on providing innovative and comprehensive solutions for blood and plasma collection, as well as transfusion medicine. This global healthcare company specializes in the development and manufacturing of devices and software that aid in blood management, including blood processing systems, information technology solutions, and donor management software. Haemonetics Corp aims to improve patient outcomes and enhance operational efficiency in blood and plasma centers, hospitals, and other healthcare settings worldwide through its integrated offerings.
Haemonetics Corp is primarily active in the healthcare industry.
Haemonetics Corp has several key competitors in the market. Some of its main competitors include Fresenius Kabi AG, B. Braun Melsungen AG, and Terumo Corporation. These companies also operate in the healthcare industry, specifically in the blood management and hematology sectors. However, Haemonetics Corp distinguishes itself through its innovative medical devices and advanced solutions, making it a formidable competitor in the market.
Haemonetics Corp is a renowned global healthcare company specializing in blood management solutions. Founded in 1971, Haemonetics has been actively shaping the medical industry for over five decades. The company's core focus lies in providing innovative devices, software, and services to enhance blood and plasma collection, processing, and transfusion. Haemonetics serves a wide range of healthcare providers, including blood banks, hospitals, and plasma fractionators. With its commitment to advancing patient care and blood safety, Haemonetics has become a trusted partner for healthcare institutions worldwide. Through continuous research and development, the company remains at the forefront of the industry, constantly expanding its product portfolio and improving blood management practices.
Haemonetics Corp has achieved several significant milestones throughout its history. One notable achievement is the development and introduction of the industry's first fully automated blood processing system, called PCS2. This innovative system has revolutionized the way blood components are collected, processed, and stored. Another important milestone for Haemonetics Corp is the acquisition of Pall Corporation's blood transfusion and filtration business in 2012, which expanded their product portfolio and global presence. Furthermore, the company has continuously focused on research and development to enhance its offerings, resulting in numerous product advancements and patents. Haemonetics Corp's commitment to innovation has solidified its position as a leading provider of blood management solutions.
Haemonetics Corp is primarily present in various countries and regions around the world. The company has a global presence and operates in several key markets including the United States, Europe, Asia-Pacific, and Latin America. It serves healthcare providers and blood banks in these regions, offering innovative blood management solutions for improved patient outcomes. Haemonetics Corp's commitment to expanding its operations internationally has allowed it to establish a strong foothold in the global healthcare industry.
Haemonetics Corp represents values of innovation, quality, and efficiency in the healthcare industry. The company is dedicated to providing advanced blood management solutions that improve patient outcomes and enhance safety. Haemonetics Corp embraces a corporate philosophy centered around collaboration, customer focus, and continuous improvement. Their commitment to delivering cutting-edge technologies and services is reflected in their strong market position and global presence. With a focus on advancing the standard of care, Haemonetics Corp strives to make a positive impact on the lives of patients and healthcare providers alike.
Analytiker sätter för närvarande ett genomsnittligt riktkurs på 95,40 USD för Haemonetics-aktien (median: 96,00 USD), vilket innebär −20,5 % mot senaste kurs. Konsensus baseras på 15 analytikerbetyg.
15 analytiker betygsätter för närvarande Haemonetics-aktien: 12 rekommenderar köp, 3 behåll och 0 sälj.
Omräknat till aktuell växelkurs handlas Haemonetics-aktien till 107,43 EUR (119,93 USD).
Haemonetics-aktien (HAE) är noterad på 3 börser, bland annat: NYSE (HAE), Frankfurt (HAZ.F), München (HAZ.MU).
Haemonetics Corp is a leading global provider of innovative blood processing systems and medical devices for the healthcare and biotechnology industries. The company offers a wide range of products divided into three main business segments: Plasma, Blood, and Hospital. The Plasma division of Haemonetics Corp focuses on the development and manufacturing of systems for the collection, processing, and storage of plasma for use in life-saving therapies. These systems are specifically designed for blood donation services, plasma collection centers, and pharmaceutical manufacturers. The company has developed a number of innovative plasma separation systems such as PCS2 and PCS2 plus, which utilize the benefits of microprocessors to automate the processing process while reducing processing time. The Blood division of the company offers a range of devices and systems for blood processing, such as the Cell Saver System for blood transfusion during surgical procedures and the OrthoPAT Advance System for the collection and processing of autologous blood for use in orthopedic procedures. The company has also developed a variety of devices to support blood transfusions, such as the TEG Systems, which provides real-time information on blood clotting. Haemonetics Corp also focuses on developing innovative solutions for hospital departments and clinical facilities. The company offers solutions for blood and plasma collection in clinical facilities and hospitals, such as the TEG 5000 Thrombelastograph Hemostasis Analyzer System or the Cell Saver Elite System, which can be used directly during surgery. The company also provides solutions for patient data management and documentation, such as eAuto Blood Bank or SafeTrace Tx blood management software, to ensure better patient care and safety. Haemonetics Corp promotes the success of its business models through a strong market presence and effective management of distribution channels. Investments in research and development have contributed to the creation of innovative products and services that provide a competitive advantage. Overall, Haemonetics Corp is a leading provider of blood processing systems and medical devices that contribute to making the healthcare industry safer and more effective. The company has the ability to adapt to rapidly changing needs while maintaining a strong leadership position in the industry.
Omsättningen för Haemonetics är 1,33 Mrd USD. Denna siffra baseras på aktuella finansiella data och återspeglar företagets affärsresultat.
Nettovinsterna för Haemonetics är 97,31 M USD. Nettovinsterna återspeglar företagets lönsamhet efter avdrag för alla utgifter.
Kurs-vinstkvoten (P/E) för Haemonetics är för närvarande 56,33. P/E-talet jämför den aktuella aktiekursen med vinsten per aktie och hjälper investerare att bedöma värderingen av Haemonetics-aktien.
Kurs-försäljningskvoten (P/S) för Haemonetics är för närvarande 4,11. P/S-talet jämför börsvärdet med den årliga omsättningen och fungerar som ett värderingsmått för Haemonetics-aktien.
Eulerpool Quality Score för Haemonetics är 2/10.
ISIN för Haemonetics är US4050241003. ISIN (International Securities Identification Number) är en globalt unik identifierare för värdepapper.
WKN för Haemonetics är 881782. WKN (Wertpapierkennnummer) är ett sexsiffrigt tyskt identifieringsnummer för värdepapper.
Tickern för Haemonetics är HAE. Tickersymbolen används för att handla Haemonetics-aktier på börsen.
Haemonetics aktie
Haemonetics Jämförbar grupp
Haemonetics Ticker
Haemonetics FIGI
Alla nyckeltal och djupgående analys av Haemonetics
Vår aktieanalys av Haemonetics-aktien innehåller viktiga finansiella nyckeltal som omsättning, vinst, P/E-tal, P/S-tal, EBIT samt information om utdelningen. Dessutom granskar vi aspekter såsom aktier, börsvärde, skulder, eget kapital och skuldförbindelser hos Haemonetics. Om du söker mer detaljerad information om dessa ämnen erbjuder vi på våra undersidor ingående analyser: